Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hernan Carol

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Pediatric Blood & Cancer|September 17, 2011
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing programMalcolm A Smith, Richard Gorlick, E Anders Kolb, et al.
Pediatric Blood & Cancer|September 24, 2015
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing programEdward F Attiyeh, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer|July 12, 2011
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Blood|June 26, 2016
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemiaSeong Lin Khaw, Santi Suryani, Kathryn Evans, et al.
Molecular Cancer Therapeutics|January 8, 2010
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Blood|June 28, 2015
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemiaDonya Moradi Manesh, Jad El-Hoss, Kathryn Evans, et al.
Pediatric Blood & Cancer|May 7, 2011
Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Pediatric Blood & Cancer|September 17, 2013
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing ProgramHernan Carol, Richard Gorlick, E Anders Kolb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2019
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)Yael P Mossé, Elizabeth Fox, David T Teachey, et al.
Plos One|August 20, 2011
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104Juliana Benito, Yuexi Shi, Barbara Szymanska, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Pediatric Blood & Cancer|September 17, 2011
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing programMalcolm A Smith, Richard Gorlick, E Anders Kolb, et al.
Pediatric Blood & Cancer|September 24, 2015
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing programEdward F Attiyeh, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer|July 12, 2011
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Blood|June 26, 2016
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemiaSeong Lin Khaw, Santi Suryani, Kathryn Evans, et al.
Molecular Cancer Therapeutics|January 8, 2010
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Blood|June 28, 2015
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemiaDonya Moradi Manesh, Jad El-Hoss, Kathryn Evans, et al.
Pediatric Blood & Cancer|May 7, 2011
Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Pediatric Blood & Cancer|September 17, 2013
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing ProgramHernan Carol, Richard Gorlick, E Anders Kolb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2019
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)Yael P Mossé, Elizabeth Fox, David T Teachey, et al.
Plos One|August 20, 2011
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104Juliana Benito, Yuexi Shi, Barbara Szymanska, et al.
Pageof 7